{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:59:12Z","timestamp":1785009552954,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Several guidelines recommend oral administration of nimodipine as vasospasm prophylaxis after aneurysmal subarachnoid hemorrhage (SAH). However, in clinical practice, the drug is administered orally and intravenously (i.v.), depending on clinical conditions and local treatment regimens. We have therefore investigated the safety and clinical effects of switching from i.v. to oral nimodipine therapy.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patients with aneurysmal SAH between January 2014 and April 2018 and initial i.v. nimodipine therapy, which was subsequently switched to oral administration, were included in this retrospective study. Transcranial Doppler sonography (TCD) of the vessels of the anterior circulation was performed daily. The occurrence of vasospasm and infarction during the overall course of the treatment was recorded. Statistical level of significance was set to <jats:italic>p<\/jats:italic> &amp;lt; 0.05.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 133 patients (mean age 55.8 years, 65% female) initially received nimodipine i.v. after aneurysmal SAH, which was subsequently switched to oral administration after a mean of 12 days. There were no significant increases in mean flow velocities on TCD after the switch from i.v. to oral nimodipine administration regarding the anterior cerebral artery. For the middle cerebral artery, an increase from 62.36 to 71.78 cm\/sec could only be detected in the subgroup of patients with infarction. There was no clustering of complicating events such as new-onset vasospasm or infarction during or after the switch.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Our results do not point to any safety concerns when switching nimodipine from initial i.v. to oral administration. Switching was neither associated with clinically relevant increases in TCD velocities nor other relevant adverse events.<\/jats:p>","DOI":"10.3389\/fneur.2021.748413","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:12:00Z","timestamp":1637043120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and Clinical Effects of Switching From Intravenous to Oral Nimodipine Administration in Aneurysmal Subarachnoid Hemorrhage"],"prefix":"10.3389","volume":"12","author":[{"given":"Jennifer","family":"G\u00f6ttsche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Schweingruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Christopher","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gerloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Czorlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1161\/STROKEAHA.110.597914","article-title":"Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects","volume":"42","author":"Vergouwen","year":"2011","journal-title":"Stroke."},{"key":"B2","first-page":"226","volume-title":"Aneurysmal Subarachnoid Hemorrhage-Diagnosis and Treatment","author":"Petridis","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1038\/s41598-020-61513-1","article-title":"Initial pupil status is a strong predictor for in-hospital mortality after aneurysmal subarachnoid hemorrhage","volume":"10","author":"Mader","year":"2020","journal-title":"Sci Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/jcbfm.2011.7","article-title":"Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis","volume":"31","author":"Etminan","year":"2011","journal-title":"J Cereb Blood Flow Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11883-017-0690-x","article-title":"Delayed cerebral ischemia after subarachnoid hemorrhage: beyond vasospasm and towards a multifactorial pathophysiology","volume":"19","author":"Geraghty","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13054-016-1193-9","article-title":"The critical care management of poor-grade subarachnoid haemorrhage","volume":"20","author":"de Oliveira Manoel","year":"2016","journal-title":"Crit Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13054-016-1447-6","article-title":"Management of delayed cerebral ischemia after subarachnoid hemorrhage","volume":"20","author":"Francoeur","year":"2016","journal-title":"Crit Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/bja\/aes264","article-title":"Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm","volume":"109","author":"Rowland","year":"2012","journal-title":"Br J Anaesth."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s12975-019-00764-1","article-title":"Immune characterization in aneurysmal subarachnoid hemorrhage reveals distinct monocytic activation and chemokine patterns","volume":"11","author":"Mohme","year":"2020","journal-title":"Transl Stroke Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/231206","article-title":"Value of perfusion CT, transcranial doppler sonography, and neurological examination to detect delayed vasospasm after aneurysmal subarachnoid hemorrhage","volume":"2012","author":"Kunze","year":"2012","journal-title":"Radiol Res Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"E175","DOI":"10.1093\/neuros\/nyz340","article-title":"Delayed cerebral infarction is systematically associated with a cerebral vasospasm of large intracranial arteries","volume":"86","author":"Brami","year":"2020","journal-title":"Clin Neurosurg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5455\/aim.2017.25.14-18","article-title":"Follow-up of vasospasm by Transcranial Doppler Sonography (TCD) in Subarachnoid Hemorrhage (SAH)","volume":"25","author":"Djelilovic-Vranic","year":"2017","journal-title":"Acta Inform Medica."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3171\/2015.4.JNS15428","article-title":"Vasospasm on transcranial Doppler is predictive of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis","volume":"124","author":"Kumar","year":"2016","journal-title":"J Neurosurg."},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/joacp.JOACP_192_17","article-title":"Monitoring cerebral vasospasm: how much can we rely on transcranial Doppler","volume":"35","author":"Samagh","year":"2019","journal-title":"J Anaesthesiol Clin Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD000277","DOI":"10.1002\/14651858.CD000277.pub3","article-title":"Calcium antagonists for aneurysmal subarachnoid haemorrhage","volume":"2007","author":"Dorhout Mees","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","first-page":"619","article-title":"Cerebral arterial spasm: a controlled trial of nimodipine in subarachnoid hemorrhage patients","volume":"308","author":"Allen","year":"1983","journal-title":"Stroke."},{"key":"B17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmj.298.6674.636","article-title":"Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial","volume":"298","author":"Pickard","year":"1989","journal-title":"Br Med J."},{"key":"B18","first-page":"IV-85","article-title":"Prevention and treatment of delayed ischemic dysfunction in patients with aneurysmal subarachnoid hemorrhage","volume":"21","author":"Tettenborn","year":"1990","journal-title":"Stroke."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1161\/01.STR.32.8.1860","article-title":"Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage","volume":"32","author":"Roos","year":"2001","journal-title":"Stroke."},{"key":"B20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.wneu.2010.02.005","article-title":"A review of delayed ischemic neurologic deficit following aneurysmal subarachnoid hemorrhage: historical overview, current treatment, and Pathophysiology","volume":"73","author":"Al-Tamimi","year":"2010","journal-title":"World Neurosurg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1055\/s-0037-1607990","article-title":"Aneurysmal Subarachnoid Hemorrhage: strategies for Preventing Vasospasm in the Intensive Care Unit","volume":"38","author":"Diringer","year":"2017","journal-title":"Semin Respir Crit Care Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","article-title":"Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the american heart association\/american stroke association","volume":"43","author":"Connolly","year":"2012","journal-title":"Stroke."},{"key":"B23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00701-015-2369-9","article-title":"Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage","volume":"157","author":"Abboud","year":"2015","journal-title":"Acta Neurochir."},{"key":"B24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.18433\/jpps30960","article-title":"The impact of nimodipine administration through feeding tube on outcomes in patients with aneurysmal subarachnoid hemorrhage","volume":"23","author":"Isse","year":"2020","journal-title":"J Pharm Pharm Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12028-015-0230-x","article-title":"Nimodipine dose reductions in the treatment of patients with aneurysmal subarachnoid hemorrhage","volume":"25","author":"Sandow","year":"2016","journal-title":"Neurocrit Care."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/1060028018778751","article-title":"Impact of early versus late intravenous followed by oral nimodipine treatment on the occurrence of delayed cerebral ischemia among patients with aneurysm subarachnoid hemorrhage","volume":"52","author":"Samseethong","year":"2018","journal-title":"Ann Pharmacother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.wneu.2011.09.030","article-title":"A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage","volume":"78","author":"Soppi","year":"2012","journal-title":"World Neurosurg."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1177\/106002809402801001","article-title":"Safety and tolerance of intravenous nimodipine","volume":"28","author":"Sramek","year":"1994","journal-title":"Ann Pharmacother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/ene.13265","article-title":"Impact of dexamethasone in patients with aneurysmal subarachnoid haemorrhage","volume":"24","author":"Czorlich","year":"2017","journal-title":"Eur J Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","article-title":"Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group","volume":"41","author":"Vergouwen","year":"2010","journal-title":"Stroke."},{"key":"B31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12028-017-0428-1","article-title":"Side effects of long-term continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after subarachnoid hemorrhage","volume":"28","author":"Kieninger","year":"2018","journal-title":"Neurocrit Care."},{"key":"B32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3171\/2008.7.JNS08178","article-title":"Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration - clinical article","volume":"110","author":"Kronvall","year":"2009","journal-title":"J Neurosurg."},{"key":"B33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12028-019-00676-w","article-title":"Incidence of arterial hypotension in patients receiving peroral or continuous intra-arterial nimodipine after aneurysmal or perimesencephalic subarachnoid hemorrhage","volume":"31","author":"Kieninger","year":"2019","journal-title":"Neurocrit Care."},{"key":"B34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.wneu.2017.03.062","article-title":"Systemic and cerebral concentration of nimodipine during established and experimental vasospasm treatment","volume":"102","author":"Albanna","year":"2017","journal-title":"World Neurosurg."},{"key":"B35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3171\/jns.1978.48.2.0173","article-title":"Time course of vasospasm in man","volume":"48","author":"Weir","year":"1978","journal-title":"J Neurosurg."},{"key":"B36","first-page":"1","volume-title":"Critical Care Secrets: Fifth Edition","author":"Parsons","year":"2012"},{"key":"B37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/STROKEAHA.116.014250","article-title":"Randomized, open-label, phase 1\/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])","volume":"48","author":"H\u00e4nggi","year":"2017","journal-title":"Stroke."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.748413\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:12:06Z","timestamp":1637043126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.748413\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":37,"alternative-id":["10.3389\/fneur.2021.748413"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.748413","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"article-number":"748413"}}